Support for A.N., A.K. and M.L.C was from an A*STAR core funding to the Experimental Therapeutics Centre. Support for C.C.D. was from UEFISCDI PCCA PN II 133/2012 and OPERATIONAL COMPETITIVITATY PROGRAM 2014-2020 POC-A1-A1.1.4-E-2015/ P_37_798/ 149/2016. S.N.C. and A.K.S. receive funding from the Ludwig Institute for Cancer Research. S.N.C. also received supports from FRS-FNRS, Salus Sanguinis Foundation, the Action de Recherche Concertée project ARC10/15–027 of the Université catholique de Louvain, the Fondation contre le Cancer, the PAI Programs BCHM61B5 and Belgian Medical Genetics Initiative.